NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Aardvark Therapeutics AARD

Aardvark Therapeutics listed on Nasdaq on 13 Feb 2025 and is not in the S&P 500. It is worth $21.9 million. Its board has 5 directors, 4 of them independent. 2 other officers are on file.

Chair and CEO
Tien-Li Lee
Listed
13 Feb 2025 on Nasdaq
Headquarters
San Diego, CA
Market cap
$22M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Aardvark Therapeutics' market cap since February 2025

Weekly, up to 13 Nov 2026

Apr 2025JulOctJan 2026AprJulOct$30M

Board and leadership

Board and officers

Board from the proxy filed 10 Jul 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (5)
Tien-Li LeeChair; Chief Executive OfficerNot independent 路 since 2017Chair; Chief Executive Officer2017No51
Roy D. BaynesDirectorIndependent 路 since 2024 路 Compensation, Nominating and Corporate GovernanceExecutive Vice President and Chief Medical Officer, Eikon Therapeutics, Inc.Other boards: Eikon Therapeutics, Natera, Travere Therapeutics and Nurix TherapeuticsDirector2024YesCompensation, Nominating and Corporate Governance71
Jeffrey ChiLead Independent DirectorIndependent 路 since 2019 路 Audit, Compensation (chair), Nominating and Corporate GovernanceSenior Consultant, Vickers Venture PartnersOther boards: Jing-jin Electric Technologies Co., Ltd.Lead Independent Director2019YesAudit, Compensation (chair), Nominating and Corporate Governance58
Susan E. GrafDirectorIndependent 路 since 2024 路 Audit (chair), CompensationSenior Advisor and Entrepreneur in Residence, Locust Walk Partners, LLCOther boards: CG OncologyDirector2024YesAudit (chair), Compensation53
Victor Edward Tong Jr.DirectorIndependent 路 since 2024 路 Audit, Nominating and Corporate Governance (chair)Managing Director, Decheng CapitalOther boards: CG OncologyDirector2024YesAudit, Nominating and Corporate Governance (chair)42
Officers (2)
Manasi JaimanChief Medical OfficerLast filed 11 Feb 2026Chief Medical Officer
Nelson SunChief Financial & Operating OfficerLast filed 11 Sep 2026Chief Financial & Operating Officer

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $394,930 of stock in 2 sales and bought $144,630 in 2 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
11 Sep 2026SaleNelson SunChief Financial & Operating OfficerChief Financial & Operating OfficerSale62,000$321K
10 Sep 2026SaleNelson SunChief Financial & Operating OfficerChief Financial & Operating OfficerSale14,754$74K
11 Dec 2025BuyTien-Li LeeChief Executive OfficerChief Executive OfficerBuy7,000$101K
11 Dec 2025BuyNelson SunChief Financial & Operating OfficerChief Financial & Operating OfficerBuy3,000$43K

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 departure and 2 appointments of directors and officers and 1 large insider sale in the last two years.

Left the company or board 1Appointed 2WARN layoff notices 0Large insider sales 1Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Aardvark Therapeutics' insider sales.

Events, newest first

Not on file: no 13F holdings reported, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.